140 related articles for article (PubMed ID: 35220216)
21. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.
Hu Q; Hu X; Zhang L; Zhao Y; Li L
Med Oncol; 2021 Mar; 38(4):41. PubMed ID: 33730237
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of miR-33a-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance.
Meng W; Tai Y; Zhao H; Fu B; Zhang T; Liu W; Li H; Yang Y; Zhang Q; Feng Y; Chen G
Med Sci Monit; 2017 Mar; 23():1295-1304. PubMed ID: 28291769
[TBL] [Abstract][Full Text] [Related]
23. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X
Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
[TBL] [Abstract][Full Text] [Related]
25. TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth.
Shen J; Lin H; Li G; Jin RA; Shi L; Chen M; Chang C; Cai X
Oncotarget; 2016 May; 7(22):32088-99. PubMed ID: 27050071
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
[TBL] [Abstract][Full Text] [Related]
27. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
[TBL] [Abstract][Full Text] [Related]
28. Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma.
Adachi Y; Matsuki M; Watanabe H; Takase K; Kodama K; Matsui J; Funahashi Y; Nomoto K
Cancer Invest; 2019; 37(4-5):185-198. PubMed ID: 31006280
[TBL] [Abstract][Full Text] [Related]
29. BCAT1, a key prognostic predictor of hepatocellular carcinoma, promotes cell proliferation and induces chemoresistance to cisplatin.
Zheng YH; Hu WJ; Chen BC; Grahn TH; Zhao YR; Bao HL; Zhu YF; Zhang QY
Liver Int; 2016 Dec; 36(12):1836-1847. PubMed ID: 27246112
[TBL] [Abstract][Full Text] [Related]
30. Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells.
Liao YJ; Bai HY; Li ZH; Zou J; Chen JW; Zheng F; Zhang JX; Mai SJ; Zeng MS; Sun HD; Pu JX; Xie D
Cell Death Dis; 2014 Mar; 5(3):e1137. PubMed ID: 24651440
[TBL] [Abstract][Full Text] [Related]
31. Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma.
Li X; Su H; Tang W; Shu S; Zhao L; Sun J; Fan H
Invest New Drugs; 2024 Apr; 42(2):185-195. PubMed ID: 38372948
[TBL] [Abstract][Full Text] [Related]
32. NQO1 Mediates Lenvatinib Resistance by Regulating ROS-induced Apoptosis in Hepatocellular Carcinoma.
Xue W; Wang T; Tian WJ; Pang SQ; Zhang HF; Jia WD
Curr Med Sci; 2024 Feb; 44(1):168-179. PubMed ID: 38217831
[TBL] [Abstract][Full Text] [Related]
33. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
[TBL] [Abstract][Full Text] [Related]
34. Silencing
Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
[TBL] [Abstract][Full Text] [Related]
35. MiR-27a-3p enhances the cisplatin sensitivity in hepatocellular carcinoma cells through inhibiting PI3K/Akt pathway.
Yang Y; Yang Z; Zhang R; Jia C; Mao R; Mahati S; Zhang Y; Wu G; Sun YN; Jia XY; Aimudula A; Zhang H; Bao Y
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34096570
[TBL] [Abstract][Full Text] [Related]
36. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
[TBL] [Abstract][Full Text] [Related]
37. Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis.
Chen L; Tian H; Li M; Ge C; Zhao F; Zhang L; Li H; Liu J; Wang T; Yao M; Li J
Tumour Biol; 2016 May; 37(5):5951-61. PubMed ID: 26596832
[TBL] [Abstract][Full Text] [Related]
38. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
39. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
Torrens L; Montironi C; Puigvehí M; Mesropian A; Leslie J; Haber PK; Maeda M; Balaseviciute U; Willoughby CE; Abril-Fornaguera J; Piqué-Gili M; Torres-Martín M; Peix J; Geh D; Ramon-Gil E; Saberi B; Friedman SL; Mann DA; Sia D; Llovet JM
Hepatology; 2021 Nov; 74(5):2652-2669. PubMed ID: 34157147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
